ArticleNeuroradiology2026
Integrated CT-PET radiogenomics and graph-based multi-task learning for preoperative prediction of key glioma molecular markers.
Article in Neuroradiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe clinical management of glioma is increasingly dependent on the tumor's molecular profile, particularly the mutation status of Isocitrate Dehydrogenase (IDH), the promoter methylation of O-6-Methylguanine-DNA Methyltransferase (MGMT), and the co-deletion of chromosomal arms 1p and 19q. Determining these markers requires invasive tissue sampling. This study aimed to develop and validate a multimodal artificial intelligence (AI) framework for the non-invasive and simultaneous prediction of these three key markers using routine preoperative CT and PET imaging.
methodsIn this multi-center, retrospective study, data from 1,472 glioma patients with confirmed histopathological diagnosis and molecular profiles were collected from four international centers. CT and PET images were fused using a Wavelet Transform. Subsequently, a comprehensive feature set was extracted, including 24 clinical variables, 3,654 radiomics features, and 43,776 deep features. The deep features were extracted from three advanced architectures: EfficientNet-B7, Swin Transformer, and DINOv3. The Boruta algorithm was used for dimensionality reduction and optimal feature selection. Finally, a Multi-Task Learning model based on a Graph Neural Network (GNN) was designed for the simultaneous prediction of IDH, MGMT, and 1p/19q status. The model's performance was evaluated using 5-fold cross-validation on the training dataset (n = 1,158) and finally validated on a completely independent external test set (n = 314).
resultsThe proposed multi-task GNN model is expected to achieve outstanding performance on the external test set: predicting IDH mutation status with an Area Under the Curve (AUC) exceeding 0.96, MGMT methylation with an AUC above 0.93, and 1p/19q co-deletion with an AUC greater than 0.95. This integrated approach is anticipated to significantly outperform models that predict each marker individually. Interpretability analysis using SHAP will reveal the combined role of clinical features (e.g., age), radiomics features (e.g., texture matrices), and deep features (e.g., abstract patterns from DINOv3) in predicting each molecular marker.
conclusionThis study introduces a powerful and integrated AI framework capable of predicting the vital molecular profile of glioma with very high accuracy and non-invasively. This tool has the potential to transform diagnostics in neuro-oncology and facilitate personalized therapeutic decision-making before surgery.
Indexed as
Identifiers
42249986What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.